These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 11871182)

  • 1. [Angiotensin 2 receptor blockaders: how do we explain the kidney-protective effect?].
    Arner P
    Lakartidningen; 2002 Jan; 99(1-2):80-2. PubMed ID: 11871182
    [No Abstract]   [Full Text] [Related]  

  • 2. [Inhibition of the renin-angiotensin system in type 2 diabetes. New significant results concerning type 2 diabetes and renal disease].
    Mogensen CE
    Ugeskr Laeger; 2001 Oct; 163(40):5488. PubMed ID: 11601112
    [No Abstract]   [Full Text] [Related]  

  • 3. [Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].
    Parving HH; Lehnert H; Brøchner-Mortensen J; Gomis R; Andersen S; Arner P
    Ugeskr Laeger; 2001 Oct; 163(40):5519-24. PubMed ID: 11601118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Diabetic patients have to be tested regularly for microalbuminuria. Almost every second one has already kidney damage].
    MMW Fortschr Med; 2004 Jan; 146(5):47. PubMed ID: 15035422
    [No Abstract]   [Full Text] [Related]  

  • 5. Preventing nephropathy in patients with type 2 diabetes.
    Manag Care Interface; 2002 Jan; 15(1):72-5. PubMed ID: 11828609
    [No Abstract]   [Full Text] [Related]  

  • 6. [Angiotensin II receptor antagonists reduce the development of nephropathies in type 2 diabetes. Three new studies are of interest, but don't answer all questions].
    Nilsson P; Attvall S
    Lakartidningen; 2001 Nov; 98(45):4960-2. PubMed ID: 11816896
    [No Abstract]   [Full Text] [Related]  

  • 7. The protective effect of blocking angiotensin in both type I and type II diabetics with nephropathy.
    Beevers DG; Lip GY
    J Hum Hypertens; 2001 Dec; 15(12):837-9. PubMed ID: 11773985
    [No Abstract]   [Full Text] [Related]  

  • 8. Renal protection by angiotensin II receptor antagonists in patients with type 2 diabetes.
    Jerums G; Cooper ME; Gilbert RE; Atkins RC
    Med J Aust; 2001 Oct; 175(8):397-9. PubMed ID: 11700829
    [No Abstract]   [Full Text] [Related]  

  • 9. [Type 2 diabetes and nephropathy--new studies, new treatment strategies?].
    Os I; Stenehjem A; Høieggen A; Draganov B; Jenssen T; Holdaas H
    Tidsskr Nor Laegeforen; 2002 Apr; 122(9):918-20. PubMed ID: 12082835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Milestone studies provide evidence: sartans have a nephroprotective effect. Evidence is clear].
    Bold KO
    MMW Fortschr Med; 2001 May; 143(22):12-3. PubMed ID: 11460392
    [No Abstract]   [Full Text] [Related]  

  • 11. Renoprotection in Type 2 diabetes: blockade of the renin-angiotensin system with angiotensin II receptor blockers.
    Swift PA; MacGregor GA
    J Renin Angiotensin Aldosterone Syst; 2001 Sep; 2(3):170-3. PubMed ID: 11881118
    [No Abstract]   [Full Text] [Related]  

  • 12. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
    Parving HH; Lehnert H; Bröchner-Mortensen J; Gomis R; Andersen S; Arner P;
    N Engl J Med; 2001 Sep; 345(12):870-8. PubMed ID: 11565519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antihypertensive therapy in renal dysfunction].
    Ito S
    Nihon Rinsho; 2003 Jul; 61(7):1210-8. PubMed ID: 12877087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evidence based treatment of diabetic nephropathy].
    Sugimoto T
    Nihon Rinsho; 2002 Oct; 60 Suppl 10():294-300. PubMed ID: 12430244
    [No Abstract]   [Full Text] [Related]  

  • 15. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy.
    Jacobsen P; Andersen S; Rossing K; Jensen BR; Parving HH
    Kidney Int; 2003 May; 63(5):1874-80. PubMed ID: 12675866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical study of the month. The CALM study assessing the combination of an angiotensin-converting enzyme inhibitor and an angiotensin II receptor antagonist in the treatment of diabetic nephropathy].
    Philips JC; Weekers L; Scheen AJ
    Rev Med Liege; 2001 Feb; 56(2):126-8. PubMed ID: 11294048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A threat to cardiovascular risk patients. "Activated renin-angiotensin system promotes end organ damage" (interview by Waldtraud Paukstadt)].
    Schunkert H
    MMW Fortschr Med; 2004 Jun; 146(23):60. PubMed ID: 15373137
    [No Abstract]   [Full Text] [Related]  

  • 18. [Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy].
    Parving HH; Brenner BM; Cooper ME; de Zeeuw D; Keane WF; Mitch WE; Remuzzi G; Snapinn SM; Zhang Z; Shahinfar S
    Ugeskr Laeger; 2001 Oct; 163(40):5514-9. PubMed ID: 11601117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of hypertension in patients with type 2 diabetes. Sartan also protects the kidneys].
    MMW Fortschr Med; 2001 Aug; 143(31-32):44. PubMed ID: 11556191
    [No Abstract]   [Full Text] [Related]  

  • 20. [Diabetic patient with hypertension takes A-I I blocker. Less likely dialysis].
    MMW Fortschr Med; 2002 Feb; 144(8):52. PubMed ID: 11910830
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.